DNA
聚合酶
药物发现
RNA聚合酶
大流行
重新调整用途
药物重新定位
计算生物学
RNA依赖性RNA聚合酶
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药品
核糖核酸
冠状病毒
病毒学
生物
生物化学
2019年冠状病毒病(COVID-19)
药理学
生物信息学
医学
基因
传染病(医学专业)
生态学
疾病
病理
作者
Heidi Tveit,Tom Kristensen
标识
DOI:10.1006/abio.2000.4903
摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, which started in late 2019, drove the scientific community to conduct innovative research to contain the spread of the pandemic and to care for those already affected. Since then, the search for new drugs that are effective against the virus has been strengthened. Featuring a relatively low cost of production under well-defined methods of cultivation, fungi have been providing a diversity of antiviral metabolites with unprecedented chemical structures. In this review, we present viral RNA infections highlighting SARS-CoV-2 morphogenesis and the infectious cycle, the targets of known antiviral drugs, and current developments in this area such as drug repurposing. We also explored the metabolic adaptability of fungi during fermentation to produce metabolites active against RNA viruses, along with their chemical structures, and mechanisms of action. Finally, the state of the art of research on SARS-CoV-2 inhibitors of fungal origin is reported, highlighting the metabolites selected by docking studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI